Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.26
−$0.61 · -7.75%
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Previous close
$7.26
−$0.61 · -7.75%
Regular session · ET · Market data may be delayed.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Day range
Current $7.26
52-week range
Current $7.26
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Sentiment
58
Mixed
Risk
74
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Day range
Current $7.26
52-week range
Current $7.26
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.8M USD | 3.6M USD | 3.31M USD | 2.67M USD | 1.56M USD |
| Selling, general, and administrative | 6.49M USD | 5.93M USD | 6.07M USD | 6.58M USD | 4.5M USD |
| Operating expenses | 16.29M USD | 9.53M USD | 9.38M USD | 9.26M USD | 6.06M USD |
| Interest income | 482.08K USD | 558.49K USD | 694.61K USD | 95.75K USD | — |
| Interest expense | — | — | — | 714.08K USD | 1.09M USD |
| Depreciation and amortization | 100K USD | 100K USD | 103.71K USD | 104.04K USD | 104.04K USD |
| Operating income | −16.29M USD | −9.53M USD | −9.38M USD | −9.26M USD | −6.06M USD |
| Net income | −15.8M USD | −8.96M USD | −8.69M USD | −9.38M USD | −21.46M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 18, 2023 | 1:12 | — | — |
Stock split | Aug 1, 2022 | 2:25 | — | — |
Stock split | Sep 24, 2021 | 1:4 | — | — |
Stock split | Oct 23, 2019 | 1:5 | — | — |
Effective Jul 18, 2023
1:12
Effective Aug 1, 2022
2:25
Effective Sep 24, 2021
1:4
Effective Oct 23, 2019
1:5
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
